Delivery Order SPE2DB20D7066-SPE2DB25FC3QG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Atomoxetine HCL 40 mg capsules (30-count) valued at $1,036.01, with an ultimate completion date of September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform fulfillment from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Atomoxetine HCL 40 mg capsules in quantities of 30 units. This contract represents a non-set-aside, competitively awarded delivery order with firm fixed pricing and a ceiling value of $1,996.53. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 2, 2025. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Atomoxetine HCL 18 mg capsules (30-count) on August 12, 2025, with a ceiling value of $1,569.60 and ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a pharmaceutical supply delivery executed through AmerisourceBergen's existing contract vehicle with DLA. The place of performance is the vendor's corporate office...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Atomoxetine HCL 18 mg capsules (30-count units) with a ceiling value of $1,535.40. This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and was awarded without set-aside restrictions through competitive procurement. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,505.60 to AmerisourceBergen Drug Corp for the supply of Atomoxetine HCL 40 mg capsules (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and is classified as a delivery order. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Atomoxetine is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Atomoxetine HCL 40 mg capsules (30-count packages) with a ceiling value of $4,835.87 and a firm fixed price structure. This contract represents a non-set-aside, competitively awarded delivery order with a completion date of September 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Atomoxetine is a selective...
- The Defense Logistics Agency awarded a delivery order valued at $1,265.16 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Atomoxetine HCL 25 mg capsules in quantities of 30. The contract utilizes firm fixed price pricing and carries an ultimate completion date of August 26, 2025. This non-set-aside competitive award will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Atomoxetine is a non-stimulant medication used primarily in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $1,007.00 to AmerisourceBergen Drug Corp for Atomoxetine HCL 80 mg capsules (30-count units) with a firm fixed price structure. The award, issued on September 19, 2025, is set to be completed by September 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a competitively awarded, non-set-aside contract with no small business restrictions. This delivery order is issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Atomoxetine 18mg tablets (30-count units) under a firm fixed-price contract valued at $2,854.91, with completion targeted for August 26, 2025. This non-set-aside competitive award represents a continuation of pharmaceutical supply fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Atomoxetine HCL 40 mg capsules. The firm-fixed-price contract, which does not have a set-aside designation, has a ceiling value of $1,891.58 and an ultimate completion date of September 30, 2024. AmerisourceBergen, through its Corporate Office Division, is a key contractor for providing a wide range of prescription medications,...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC3QGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Atomoxetine HCL 60 mg capsules (30-count units) with a ceiling value of $1,012.36. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and specifies a place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters is located. AmerisourceBergen Drug Corp, a major pharmaceutical distributor serving the federal medical procurement market, fulfills critical supply needs for the Defense Health Agency and military healthcare systems through its comprehensive pharmaceutical portfolio. This delivery order for Atomoxetine HCL—a medication commonly used for attention deficit hyperactivity disorder treatment—demonstrates the company's role in supplying specialized neurological medications to support military and veteran healthcare programs. The ultimate completion date is set for June 6, 2025, reflecting the expedited nature of this pharmaceutical delivery order.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 6/5/25 |